LSTA icon

Lisata Therapeutics

2.53 USD
+0.00
0.00%
Updated Jul 31, 11:22 AM EDT
1 day
0.00%
5 days
-4.53%
1 month
-12.76%
3 months
6.75%
6 months
1.20%
Year to date
-29.13%
1 year
-21.43%
5 years
-92.57%
10 years
-98.98%
 

About: Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Employees: 26

0
Funds holding %
of 7,324 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

10% more funds holding

Funds holding: 21 [Q4 2024] → 23 (+2) [Q1 2025]

0.27% less ownership

Funds ownership: 9.35% [Q4 2024] → 9.09% (-0.27%) [Q1 2025]

21% less capital invested

Capital invested by funds: $2.33M [Q4 2024] → $1.84M (-$493K) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$32
1,165%
upside
Avg. target
$32
1,165%
upside
High target
$32
1,165%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Brookline Capital
Kemp Dolliver
1,165%upside
$32
Buy
Maintained
15 Jul 2025

Financial journalist opinion

Based on 6 articles about LSTA published over the past 30 days

Neutral
GlobeNewsWire
4 hours ago
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, after the close of trading and will host a conference call at 4:30 p.m.
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
Positive
Proactive Investors
2 weeks ago
Lisata Therapeutics and WARPNINE complete enrollment in iLSTA trial, share encouraging preliminary results
Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE announced the completion of patient enrollment in the Phase 1b/2a iLSTA trial, which is evaluating Lisata's therapy candidate certepetide in combination with standard-of-care chemotherapy and immunotherapy in pancreatic cancer. It is evaluating the therapy in patients with locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC), rather than metastatic PDAC.
Lisata Therapeutics and WARPNINE complete enrollment in iLSTA trial, share encouraging preliminary results
Neutral
GlobeNewsWire
2 weeks ago
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide's potential ability to enhance the effectiveness of immunotherapy Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide's potential ability to enhance the effectiveness of immunotherapy
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
Positive
Proactive Investors
2 weeks ago
Lisata Therapeutics expands IP with key patent covering certepetide's chemical structure and uses
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has been issued a new US composition of matter patent for its investigational drug candidate certepetide. The United States Patent and Trademark Office (USPTO) has granted the company US Patent No 12,351,653, which provides protection for certepetide through March 2040, with the possibility of a patent term extension.
Lisata Therapeutics expands IP with key patent covering certepetide's chemical structure and uses
Neutral
GlobeNewsWire
2 weeks ago
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
Positive
Proactive Investors
2 weeks ago
Lisata Therapeutics and GATC advance AI-driven opioid use disorder therapy - ICYMI
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company's deepening collaboration with GATC Health. Mazzo explained that the partnership has evolved due to the complementary strengths of both organisations—Lisata's clinical and regulatory expertise and GATC's AI-powered drug discovery platform, MAT.
Lisata Therapeutics and GATC advance AI-driven opioid use disorder therapy - ICYMI
Positive
Proactive Investors
1 month ago
Lisata Therapeutics reports encouraging data from ASCEND Cohort B evaluating certepetide in pancreatic cancer
Lisata Therapeutics Inc (NASDAQ:LSTA), in collaboration with the Australasian Gastro-Intestinal Trials Group and the NHMRC Clinical Trials Centre at the University of Sydney, announced positive preliminary results from Cohort B of the ASCEND Phase 2b clinical trial evaluating certepetide in combination with standard-of-care chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). The ASCEND trial is a 158-patient, double-blind, randomized, placebo-controlled study assessing the addition of certepetide to standard-of-care gemcitabine and nab-paclitaxel.
Lisata Therapeutics reports encouraging data from ASCEND Cohort B evaluating certepetide in pancreatic cancer
Positive
Proactive Investors
1 month ago
Lisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC Health
Lisata Therapeutics Inc (NASDAQ:LSTA) and GATC Health have expanded their strategic alliance aimed at accelerating and improving the success rate of drug development using artificial intelligence (AI). The expanded collaboration builds on prior work in which GATC provided AI-based analysis supporting Lisata's certepetide drug candidate.
Lisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC Health
Neutral
GlobeNewsWire
1 month ago
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
Expanded alliance combines Lisata's drug development expertise with GATC's AI-powered Multiomics Advanced Technology® platform to accelerate and improve success rates of next-generation drug development
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
Neutral
GlobeNewsWire
1 month ago
Lisata Therapeutics to Present at the 2025 BIO International Convention
BASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present a corporate overview at the upcoming 2025 BIO International Convention taking place in Boston, MA from June 16 – 19, 2025.
Lisata Therapeutics to Present at the 2025 BIO International Convention
Charts implemented using Lightweight Charts™